Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)
Conditions: Chronic Hepatitis C
Sponsor: AbbVie

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 1 of 65
Title Page  
Title
Real World Evidence of the Effectiveness of Paritaprevir/r 
– Ombitasvir, ±Dasabuvir, ± Ribavirin in Patients with 
Chronic Hepatitis C - 
An Observational Study in Canada (AMBER) 
Protocol Version 
Identifier
Protocol Version 2.0 (12 January 2016) 
Date of Last Version of 
Protocol
15 June 2015
Research Question and 
Objectives
What is the effectiveness and patient reported outcome of 
the interferon-free regimen of paritaprevir/r – ombitasvir, ± 
dasabuvir, ± ribavirin in patients with CHC in a real life 
setting across clinical practice patient populations?
Country(-ies) of Study
Canada
Main Author
Marketing Authorization
Holder(s)
AbbVie Corporation
This study will be conducted in compliance with this protocol and all applicable 
local regulatory requirements

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 2 of 65
1.0
Table of Contents
1.0
Table of Contents.....................................................................2
2.0 
Abbreviations...........................................................................5 
3.0 
Responsible Parties..................................................................8 
4.0
Abstract ....................................................................................9
5.0 
Amendments and Updates....................................................13 
6.0 
Milestones...............................................................................13 
7.0
Rationale and Background...................................................14
7.1 
Background..............................................................................................14 
7.2 
Rationale ..................................................................................................19 
8.0
Research Question and Objectives ......................................21
8.1 
Research Question ...................................................................................21 
8.2 
Objectives ................................................................................................21 
 
Primary Objective ....................................................................................21
8.2.1
 
Secondary Objectives...............................................................................21 
8.2.2
9.0 
Research Methods..................................................................22 
9.1
Study Design............................................................................................22
9.2 
Setting ......................................................................................................23 
 
Target Population.....................................................................................23 
9.2.1
Study Duration.........................................................................................24
9.2.2
 
Termination Criteria.................................................................................24 
9.2.3
 
Investigator Selection Criteria .................................................................24 
9.2.4
9.3
Variables ..................................................................................................24
 
Primary Variable......................................................................................24 
9.3.1
 
Secondary Variables ................................................................................25 
9.3.2
9.4
Data Sources ............................................................................................25
 
Data to be Documented............................................................................25 
9.4.1
9.4.1.1 
Inclusion Documentation.........................................................................26 
9.4.1.2
During Treatment Documentation ...........................................................27
9.4.1.3 
Post-Treatment Documentation ...............................................................27 
9.4.1.4 
HCV RNA Sample...................................................................................30 
9.4.1.5
Concomitant Medication..........................................................................30

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 3 of 65
9.4.1.6 
Standardized Assessment Tools...............................................................30 
9.5 
Study Size ................................................................................................32 
9.6 
Data Management ....................................................................................33 
 
Electronic Case Report Forms .................................................................33 
9.6.1
 
Handling of Questionnaires .....................................................................34 
9.6.2
 
Assignment of Preferred Terms...............................................................34 
9.6.3
9.7 
Data Analysis...........................................................................................35 
 
Analysis Population, Time Windows and Handling of Missing 
9.7.1
Data..........................................................................................................35 
 
Demographics and Disease Characteristics .............................................36 
9.7.2
 
Effectiveness Analysis.............................................................................37 
9.7.3
9.7.3.1 
Primary Effectiveness Endpoint ..............................................................37 
9.7.3.2 
Secondary Effectiveness Endpoints.........................................................37 
9.7.3.3 
Statistical Methods for Analysis of Effectiveness Variables...................38 
 
Clinical Laboratory Data..........................................................................39 
9.7.4
 
PRO Questionnaires.................................................................................40 
9.7.5
 
PSP, PAM and BMQ ...............................................................................41 
9.7.6
 
Resource Utilization.................................................................................42 
9.7.7
 
Tolerability Analysis................................................................................42 
9.7.8
 
Interim Assessments ................................................................................43 
9.7.9
9.8 
Quality Control ........................................................................................43 
9.9 
Limitations of the Research Methods ......................................................43 
10.0 
Protection of Human Subjects..............................................44 
11.0 
Management and Reporting of Complaints........................44 
11.1 
Medical Complaints.................................................................................45 
 
Adverse Event Definition and Serious Adverse Event Categories..........45 
11.1.1
 
Severity ....................................................................................................47 
11.1.2
 
Relationship to Pharmaceutical Product ..................................................47 
11.1.3
 
Serious Adverse Event Collection Period................................................47 
11.1.4
 
Serious and non-serious Adverse Event Reporting..................................47 
11.1.5
 
Pregnancy Reporting................................................................................48 
11.1.6
 
Unusual Failure in Efficacy .....................................................................48 
11.1.7
11.2 
Product Complaint ...................................................................................49 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 4 of 65
 
Definition .................................................................................................49 
11.2.1
 
Reporting..................................................................................................49 
11.2.2
12.0 
Plans for Disseminating and Communicating Study 
Results.....................................................................................49 
13.0 
References...............................................................................51 
Annex 1. 
EQ5D-5L.................................................................................56 
Annex 2. 
WPAI ......................................................................................58 
Annex 3. 
PAM-13 Questionnaire Sample............................................60 
Annex 4. 
Beliefs Medication Questionnaire (BMQ)...........................61 
Annex 5. 
Patient Support Program (PSP) Utilization 
Questionnaire.........................................................................62 
Annex 6. 
Patient Support Program (PSP) Utilization and -
Satisfaction Questionnaire....................................................63 
Annex 7. 
Child-Pugh Classification of Severity of Cirrhosis ............64 
14.0 
Protocol Signature Page........................................................65 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 5 of 65
2.0
Abbreviations
AE
adverse event
APRI
AST to platelet ratio index
AFP
alfa fetoprotein
ALT
alanine-aminotransferase
AST
aspartate-aminotransferase
ABBVIE
REGIMEN
Paritaprevir/r – ombitasvir ± dasabuvir
ANCOVA
analysis of covariance
BMI
body mass index
BMQ
beliefs medication questionnaire
CA
competent authority
CD4
cluster of differentiation 4
CHC
chronic hepatitis C
CI
confidence interval
CNI
calcineurin
CP
core population
CPFSU
core population with sufficient follow-up data
CT
computer tomography
DAA
direct-acting antiviral agent
DDI
drug-drug interaction
EC
ethics committee
EDC
electronic data capture
eCRF
electronic case report form
EMA
European Medicines Agency
EoT
end of treatment
EQ-5D-5L
EuroQol 5 dimension 5 level
FDA
Food and Drug Administration
FIB-4
Fibrosis-4 Score/Index

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 6 of 65
Ȗ-GT
gamma-glutamyltransferase
HCC
hepatocellular carcinoma
HCP
health care provider
Hb
hemoglobin
HbA1c
hemoglobin A1c
HBV
hepatitis B virus
HCV
hepatitis C virus
HDL
high-density lipoprotein
HIV
human immunodeficiency virus
HOMA
homeostasis model assessment
HVPG
hepatic venous pressure gradient
ICMJE
International Committee of Medical Journal Editors
IEC/IRB
independent ethics committee/- review board
IgA
Immunoglobulin A
IgG
Immunoglobulin G
IgM
Immunoglobulin M
INN
international non-proprietary name
INR
international normalized ratio
LDL
low-density lipoprotein
LLoD
lower limit of detection
LLoQ
lower limit of quantification
MAH
Marketing Authorization Holder
MedDRA
Medical Dictionary for Regulatory Activities
MLR
multiple logistic regression
MRI
magnetic resonance imaging
NCP
non-core population
NS3/NS4A
nonstructural protein 3/nonstructural protein 4A
NS5A
nonstructural protein 5A
NS5B
nonstructural protein 5B

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 7 of 65
OATP
organic anion-transporting polypeptide
OLT
orthotopic liver transplant
PAM-13
Patient Activation Measure 13
PCR
polymerase chain reaction
pegIFN
pegylated interferon
PRO
patient reported outcome
PSP
patient support program
PT
preferred term
RBV 
ribavirin
RF
rheumatoid factor
RNA
ribonucleic acid
SAE
serious adverse event
SAP
statistical analysis plan
SD
standard deviation
SDP
study designated physician
SNP
single nucleotide polymorphism
SOC
system organ class
SP
safety population
SVR
sustained virological response
SVR12
SVR at 12 weeks after EoT
SVR24
SVR at 24 weeks after EoT
TAI
total activity impairment
TP
target population
TWP
total work productivity impairment
VAS
visual analogue scale
WHO
World Health Organization
WPAI
work productivity and activity impairment
WPAI-GH
WPAI as general health measure
WPAI-SHP
WPAI modified for specific health condition

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 8 of 65
3.0
Responsible Parties  
Study Designated Physician (SDP):
Protocol Authors: 
  
Vendor:
x
IST GmbH, Soldnerstrasse 1, D-68219 Mannheim, Germany
www.istgmbh.com
Contract Research Organization: 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 9 of 65
4.0
Abstract
Title:
Real World Evidence of the Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin 
in Patients with Chronic Hepatitis C –
An Observational Study in Canada (AMBER)
Rationale and Background:
The interferon-free combination regimen of paritaprevir/r – ombitasvir with or without dasabuvir 
(ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been 
shown to be safe and effective in randomized controlled clinical trials with strict inclusion and 
exclusion criteria under well controlled conditions.
The ABBVIE REGIMEN received market authorization in Canada on December 22, 2014.  
The rationale for this observational study is to determine how the efficacy and safety of the 
ABBVIE REGIMEN as demonstrated in pivotal trials translates into real world everyday clinical 
settings, which means evaluating its effectiveness. Whereas efficacy can be defined as a 
measure of the capacity of a treatment to produce the desired effect in a controlled 
environment, such as in a randomized controlled trial, effectiveness is the extent to which a drug 
achieves its intended effect in the usual clinical setting. Effectiveness trials typically have limited 
exclusion criteria and will involve the broader patient populations in routine clinical practice and 
per local label which might include patients with heterogenous compliance patterns and patients 
with significant comorbid conditions and could be used to model and disseminate best practices.
Effectiveness research allows for external patient-, provider-, and system-level factors and can 
therefore be more relevant for health-care decisions by both providers in practice and policy-
makers.
This observational study is the first effectiveness research examining the ABBVIE REGIMEN ±
RBV, used according to local label, under real world conditions in Canada in a clinical practice 
patient population.
During the last decade when dual therapy with pegylated interferon (pegIFN) plus RBV was 
standard of care for the treatment of CHC, the discovery of predictive factors for virological 
response and the subsequent development of treatment algorithms marked a milestone in 
patient care for CHC. As a consequence, treatment could be effectively targeted to patients 
most likely to respond. Interestingly, many of the now well established predictors of response to 
pegIFN/RBV and first generation direct acting antivirals (DAAs) in combination with pegIFN/RBV 
were not predictive of outcome in the development trials of the ABBVIE REGIMEN ± RBV. This
observational study may play an important part in bridging the data gaps. It may help identify 
predictive factors of response that are important in real world treatment settings and thus, could
assist in further optimizing treatment with the interferon-free ABBVIE REGIMEN ± RBV in the 
future.
The label of the ABBVIE REGIMEN ± RBV will vary according to hepatitis C virus (HCV)
genotype/subtype and stage of liver disease. It is therefore relevant to understand the pattern of 
use and outcome in daily clinical practice. In addition, this study will provide data on the impact 
of adherence on treatment outcomes in everyday settings, which may help treating physicians 
to improve the management of patients under their care.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 10 of 65
The aim of this observational study is to provide evidence of the effectiveness and patient 
reported outcome (PRO) of the ABBVIE REGIMEN ± RBV and to describe work productivity, 
healthcare resource utilization and the contribution of a patient support program in a real world 
setting across clinical practice patient populations.
Research Question and Objectives:
What is the effectiveness and patient reported outcome of the interferon-free ABBVIE 
REGIMEN ± RBV in patients with CHC in a real life setting across clinical practice patient 
populations?
Primary Objective
1.
To describe in routine clinical practice the effectiveness of the interferon-free 
ABBVIE REGIMEN ± RBV in patients with CHC as evidenced by sustained 
virological response at 12 weeks after end of treatment (SVR12)
Secondary Objectives
2.
To describe the pattern of real world use of the ABBVIE REGIMEN ± RBV with 
respect to different patient and treatment characteristics 
3.
To evaluate the influence of adherence on treatment outcome in routine clinical 
practice
4.
To describe the tolerability of the ABBVIE REGIMEN ± RBV
5.
To document the effect of the ABBVIE REGIMEN ± RBV on PROs and work 
productivity in the Canadian population 
6.
To determine the impact of the ABBVIE REGIMEN ± RBV on healthcare resource 
utilization
7.
To evaluate the contribution of the patient support program (PSP) to disease 
control, treatment continuation over time, patient satisfaction and PSP utilization
Study Design:
This is a prospective, multi-center observational study in patients receiving the interferon-free 
ABBVIE REGIMEN ± RBV.
The prescription of a treatment regimen is at the discretion of the physician in accordance with 
local clinical practice and label, is made independently from this observational study and 
precedes the decision to offer the patient the opportunity to participate in this study.
Target Population:
Patients are eligible for observation in this cohort if the following applies:
x
Treatment-naïve or -experienced adult male or female patients with confirmed CHC,
genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE 
REGIMEN ± RBV according to standard of care and in line with the current local label
x
If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line 
with the current local label (with special attention to contraception requirements and 
contraindication during pregnancy) 
x
Patients must voluntarily sign and date a patient authorization to use and/or disclose 
his/her anonymized health data prior to inclusion into the study
x
Patient must not be participating or intending to participate in a concurrent interventional 
therapeutic trial

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 11 of 65
Variables:
Primary Variable
x
7KHSHUFHQWDJHRISDWLHQWVDFKLHYLQJ695+&951$,8P/ZHHNV>LH
days] after the last actual dose of the ABBVIE REGIMEN)
Secondary Variables
x
Type of treatment regimen (± dasabuvir, ± RBV, intended and actual combination, dose 
and duration)
x
Adherence
o
Percentage of the DAA dose taken in relation to the target dose of DAA 
(cumulative dose taken divided by target dose in percent)
o
Percentage of the RBV dose taken in relation to the target dose of RBV 
(cumulative dose taken divided by target dose in percent)
o
Percentage of missed RBV treatment days in relation to the target number of 
RBV treatment days
x
Serious and non-serious adverse events and pregnancy occurrences
x
Questionnaires on PROs: EuroQol 5 dimension 5 level (EQ-5D-5L) questionnaire and 
work productivity and activity impairment (WPAI) questionnaire prior to treatment 
initiation, at EoT as well as 12 and 24 weeks after EoT
x
PAM-13, BMQ, PSP utilization and satisfaction questionnaires
Data Sources:
Source documents are defined as original documents. The investigator will document patient 
data in his/her own patient files which will serve as source data for the study.
Study Size: 
In phase III studies investigating the interferon-free ABBVIE REGIMEN ± RBV, SVR12 rates of 
at least 90% were observed, even in difficult-to-treat CHC patients (e.g. cirrhotic G1a treatment 
experienced patients). To describe in routine clinical practice the effectiveness of the ABBVIE 
REGIMEN ± RBV in patients with CHC, a precise estimate of the SVR12 rates should be 
achieved.
It is expected, that during the planned inclusion period of 24 months about 600 – 800 patients 
treated with the ABBVIE REGIMEN ± RBV can be included. With 800 evaluable patients the 
width of the 95% confidence interval (CI) will be 4.3% and 3.2% for SVR12 rates of 90% and 
95%, respectively. If only 600 patients can be evaluated, the 95% CI will have a width of less 
than 5% for a SVR12 rate of at least 90% and less than 4% for a SVR12 rate of at least 95%. In 
summary, a sample size of 600 to 800 patients will provide sufficient precision for the estimation 
of the SVR12 rates.
Data Analysis:
The core population (CP) is defined as all patients of the target population (TP) (definition see
above), who have started the treatment combination recommended in the current local label for 
their disease characteristics. Patients not receiving the treatment recommended in the local 
label will be summarized in the non-core population (NCP). In addition, the core population with 
sufficient follow-up data (CPSFU) is defined as all CP patients, who have (i) evaluable HCV 
51$GDWDGD\VDIWHUWKHODVWDFWXDOGRVHRIWKHABBVIE REGIMEN or (ii) a HCV RNA value 
50 IU/mL at the last measurement or (iii) had HCV RNA <50 IU/mL at the last measurement, 
EXWQR+&951$PHDVXUHPHQWGD\VDIWHUWKHODVWDFWXDOGRVHRIWKHABBVIE REGIMEN

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 12 of 65
due to reasons related to safety (e.g. dropped out due to adverse event) or incomplete efficacy 
information (e.g. virologic failure such as relapse is reported in the electronic case report form
(eCRF) but date and value of the corresponding HCV RNA test is missing). The safety 
population (SP) is defined as all patients who received at least one dose of the ABBVIE 
REGIMEN.
Descriptive and exploratory statistical methods will be used to analyze the data of the study. All 
baseline and disease characteristics will be summarized for the CP stratified by the CP analysis 
groups (based on genotype 1 subtype, fibrosis status, treatment experienced or naïve), which 
are relevant for scheduled treatment combination (± dasabuvir, ± RBV) and duration (12 or 24
weeks). In addition, baseline summaries will be repeated for the SP and TP without stratification 
into subgroups. Further details of analysis populations and the CP analysis groups will be 
specified in the statistical analysis plan (SAP).
The primary effectiveness analysis will be performed for CP patients, stratified by the CP 
analysis groups. Response rates (i.e. SVR12 rate, end of treatment [EoT] response rate,
relapse rate, viral breakthrough) will be determined for the various CP analysis groups. The
relapse rates will be estimated in patients of the CP analysis groups with EoT response and 
sufficient HCV RNA measurements post treatment. Viral breakthrough rates will be estimated in 
all patients of the CP analysis groups, who have at least one undetectable HCV RNA 
measurement on treatment and at least one on-treatment or EoT measurement thereafter. For 
all rates specified above 95%-confidence intervals (CIs) will be determined using the Clopper-
Pearson method.
Univariate and multiple logistic regression (MLR) methods will be used to investigate the impact 
of various explanatory covariates (e.g. demographic and disease characteristics, co-morbidities, 
type of treating institution, and prior treatment for CHC and response outcome in treatment 
experienced patients) on SVR12. These analyses will be of exploratory nature, data driven, and 
will be performed for various CP analysis groups since not each covariate might be predictive in 
each patient group. Furthermore, the fact that treatment regimens will differ in the various 
patient groups has to be taken into account, when selecting the patient groups for each MLR 
analysis. Backward selection procedures will be applied to generate the final MLR models which
will consider only covariates in the selection procedure with a p-value <0.25 in the 
corresponding univariate logistic regression analysis. A p-value <0.05 will be used for the 
covariates to stay in the model in a backward elimination step. Logistic regression methods will 
also be used to investigate the impact of treatment adherence on SVR12. 
All safety variables will be summarized for patients in the SP using descriptive statistical 
methods stratified by the type of combination treatment and scheduled treatment duration.
Milestones:
Start of Data Collection: 
October 2015
End of Data Collection:
September 2018
Final Report of Study Results: 
August 2019

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 13 of 65
5.0
Amendments and Updates
Number
Date
Section of Study 
Protocol
Amendment 
or Update
Reason
1
12 January 2016
Title
Title Page
4.0 (Background and 
Rationale, Target 
Population, Secondary 
Variables, Data Analysis)
9.2.1
9.3.2
14.0
Amendment
Inclusion of 
patients with 
genotype 4 into the 
study. Approval for 
treatment of G4 
with paritaprevir/r –
ombitasvir + RBV
granted in Canada 
on 19 October
2015
2
12 January 2016
4.0. (Milestones), 6.0 
Update
Study start in 
October 2015
3
12 January 2016
9.7.9
Amendment
Further interim 
analysis planned
4
12 January 2016
11.0
11.2
Amendment
Header changed 
Text on product 
complaint added
5
12 January 2016
Annex 4
Update
Revised version of 
BMQ
questionnaire used
6.0
Milestones
x
Start of Data Collection:
October 2015
x
End of Data Collection:
September 2018
x
Final Report of Study Results:
August 2019

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 14 of 65
7.0
Rationale and Background
7.1
Background
Infection with the hepatitis C virus (HCV) is associated with considerable morbidity and 
mortality [1] and is a leading cause of chronic liver disease, cirrhosis, and hepatocellular 
carcinoma (HCC), as well as the most common indication for liver transplantation in 
many countries [2]. Around 60-85% of subjects exposed to HCV do not clear the virus 
and go on to develop chronic disease [3] [4]. Chronic hepatitis C (CHC) affects an 
estimated 2-3% of the world’s population - equaling approximately 130-210 million
individuals [5] [6]. The prevalence varies markedly from one geographic area to another 
ranging from 0.1-1% in Western Europe to 1-2% in Latin America and up to 4.9% in 
some regions of Eastern Europe [7] [8] [9] [10].
HCV demonstrates a high degree of genetic variability and has been classified into seven
major genotypes (and a large number of subtypes) the distribution of which varies 
globally [11]. Genotypes 1 through 3 are found worldwide; the other genotypes have a 
more restricted distribution, genotype 4 is found predominantly in the Middle East, 
Central Africa, and Egypt; genotype 5 in South Africa; and genotype 6 mainly in Asia. 
HCV genotypes 1a and 1b are the most common forms, accounting for 60% of HCV 
infections worldwide [12] [13] [14] [15].
HCV is primarily transmitted by parenteral exposures to contaminated blood, most 
frequently by injection drug use, exposures in health-care settings and inadequate 
infection-control practices (tattoo, piercing). Occupational, perinatal and sexual exposure 
can also result in transmission of HCV [16] [17]. Since the early 1990’s routine blood
screening protocols have been introduced in most countries and as a consequence 
transmission of the virus is rarely seen following receipt of blood, blood products or 
through organ transplants.
The natural course of CHC leads to progressive fibrosis and can eventually lead to 
cirrhosis of the liver over the course of 20-30 years in approximately 15-30% of infected 
individuals [18]. Once patients become cirrhotic, around 6% per year are expected to 
develop hepatic decompensation (ascites, encephalopathy, variceal hemorrhage, 
hepatorenal syndrome, or hepatic synthetic dysfunction) and around 3% per year will 
develop HCC [19]. Over the same time frame, between 4 and 5% of patients can be 
expected to require liver transplantation or die [19] [20]. Progression is not necessarily a 
linear process and can be accelerated by a number of factors including the age of the 
patient, duration of HCV infection, male gender, alcohol consumption and co-infection 
with other viruses such as hepatitis B virus (HBV) and human immunodeficiency virus 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 15 of 65
(HIV) [4] but also by concomitant steatosis and obesity. Comorbid conditions can impact 
CHC treatment eligibility, safety, tolerability and efficacy of therapy [21] [22].
The burden of advanced liver disease varies widely across countries and is dependent 
upon several factors including chronic HCV prevalence and age distribution (and duration 
of infection) of those infected [23]. Due to an aging cohort of patients and an associated 
increase in the incidence of severe liver disease, the burden of CHC will continue to 
increase. In persons 30–49 years of age, the prevalence of the disease is 3–fold higher 
than in other age groups. By 2020, the rates of HCC and liver-related deaths among 
individuals with CHC are expected to increase by 81% and 180%, respectively [24].
The eradication of the virus, defined as the absence of HCV ribonucleic acid (RNA) in 
serum (as shown by a sensitive test) at the end of treatment (EoT) and 12-24 weeks later 
(sustained virological response [SVR]), is the therapeutic goal of CHC treatment [25] [26]
[27] and is generally accepted as a virological cure, thus, eventually preventing the 
aforementioned complications [26] [27].
Achieving an SVR was associated with significant reduction in all-cause death compared 
to patients who did not achieve SVR (5-year mortality rate in HCV genotype 1-infected 
patients: 6.7% vs 14.4%, respectively) [28]. In another study the 10-year cumulative all-
cause mortality rate was 8.9% in patients with SVR and 26.0% without SVR (p<0.001), 
the liver-related mortality or transplantation was 1.9% with SVR and 27.4% without SVR
(p<0.001), the rate of HCC was 5.1% with and 21.8% without SVR (p<0.001), and the 
rate of patients experiencing liver failure was 2.1% with and 29.9% (p<0.001) without 
SVR [29]. Patients with SVR following treatment with pegylated interferon (pegIFN) with 
or without RBV have also shown improvement in liver histology and a reduction in liver-
related death in several studies [30] [31] [32]. Moreover, patients with compensated 
cirrhosis who achieve SVR essentially eliminate their subsequent risk of 
decompensation, may achieve histologic regression, and decrease their risk of HCC by 
two-thirds [33] [34] [35].
In the 1980’s and 1990’s interferon alfa was the first drug to show activity against HCV. 
However, the effectiveness of interferon monotherapy in the treatment of CHC infection 
was generally unsatisfactory resulting in an overall SVR rate across genotypes of <20% 
[36] [37]. Combination therapy with interferon plus ribavirin (RBV) improved SVR rates 
but still overall rates across genotypes remained below 50% [38] [39]. Following the 
introduction of long-acting interferons (peginterferon alfa-2a and peginterferon alfa-2b
[i.e. pegIFNs]) in combination with RBV more than a decade ago, further advances have 
been made in efficacy with overall rates of SVR up to 54-63% [39] [40] [41]. SVR rates 
vary substantially by HCV genotype with genotype 1 being the most difficult-to-treat, thus 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 16 of 65
requiring longer treatment periods to obtain SVR with interferon-based dual therapy. SVR 
rates up to around 50% can be achieved in patients with genotype 1 whereas for 
genotypes 2 and 3 cure rates of up to 80% can be achieved [41].
Treatment with pegIFN and RBV is associated with considerable, often treatment-limiting
toxicities including cytopenias, neuro-psychiatric disorders and influenza-like symptoms.
In 2011 the first direct-acting antivirals (DAAs), specifically the protease inhibitors 
boceprevir and telaprevir, have been approved by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) for treatment of HCV genotype 1.
These first generation DAAs have significantly improved efficacy with rates of SVR 
reported as high as 63-75% among treatment-naïve HCV genotype 1 individuals [42] [43]
[44]. However, these DAAs must be used in combination with pegIFN and RBV as triple
combination therapy and the tolerability profile is further impaired by additional DAA
specific adverse effects such as rash, pruritus, dysgeusia and anemia [42] [43] [44].
Treatment regimens with these DAAs are rather complicated with the necessity of futility 
rules and a response guided therapy duration of up to 48 weeks in selected patients.
Since 2014 the new standard of care for genotype 1 is pegIFN and RBV combined with 
either the nonstructural protein 3/nonstructural protein 4A (NS3/4A) protease inhibitor 
simeprevir or the nucleotide nonstructural protein 5B (NS5B) polymerase inhibitor 
sofosbuvir [45] [46].
Simeprevir is a NS3/4A protease inhibitor which was approved by the FDA at the end of 
2013 and by the EMA in May 2014. In the phase III studies QUEST 1 and 2 treatment-
naïve patients with genotype 1 yielded SVR rates of 80%, around 90% of these patients 
were eligible for truncated therapy of 24 weeks in a response guided treatment setting 
[47] [48]. Very similar results were reported for patients with prior relapse in the 
PROMISE trial [49]. In the ATTAIN study 771 treatment-experienced partial and null-
responder patients were randomized to either simeprevir plus pegIFN and RBV or 
telaprevir plus pegIFN and RBV. Although efficacy rates were similar (SVR was 55% and
54%, respectively) the safety profile of simeprevir was significantly improved, in particular 
with regards to anemia (13% vs. 37%) and pruritus (31% vs. 43%), while serious adverse 
events (SAEs) were reported by 2% and 9% of patients, respectively [50].
Notably, among patients infected with HCV genotype 1a the presence of a common
Q80K polymorphism (pre-existing resistance-associated variant or not) results in 
significantly reduced response rates and thus, it is recommended that patients infected 
with HCV genotype 1a are screened for this mutation, and if the respective variant is 
present, consideration is given to selecting an alternative therapy [51].

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 17 of 65
Sofosbuvir acts as an RNA chain terminator within the catalytic site of the NS5B 
polymerase. It was approved by the FDA in December 2013 and by the EMA in January 
2014 for treatment of genotype 1, 4, 5, and 6 along with pegIFN plus RBV and in 
genotype 2 and 3 patients as an interferon-free regimen with RBV only.
In the NEUTRINO phase III trial with sofosbuvir plus pegIFN/RBV in 326 treatment-naïve 
genotype 1, 4, 5 and 6 patients, the overall SVR was 90% (92% in genotype 1a and 82% 
in genotype 1b; 80% in cirrhotic patients) with a tolerability profile similar to pegIFN plus 
RBV. One further advantage of this triple treatment regimen is the treatment duration of 
just 12 weeks [52].
Data on the interferon-free combination of sofosbuvir plus RBV in treatment-naïve 
patients with genotype 1 are only available from small trials and results are somewhat 
inconsistent. When given for a duration of 24 weeks SVR rates of 50-68% have been 
reported and this regimen is currently only recommended for patients who cannot take 
pegIFN [45] [46] [53] [54].
Thus, currently available approved treatment regimens are not optimal for many patients 
and there is a clear unmet need for effective anti-HCV compounds which can increase 
the likelihood of successful treatment and/or decrease the need for pegIFN as 
components of CHC therapy, ideally with shorter treatment duration.
Combinations of multiple DAAs targeting different steps of viral replication have the 
potential to significantly improve CHC treatment compared to current therapies by 
increasing SVR rates, eliminating interferon as a component of therapy, increasing the 
safety and tolerability of treatment, shortening duration of therapy and simplifying the 
treatment algorithm. In addition, wider application of DAA therapy and better responses 
with combination DAA regimens could significantly reduce the public health burden of this 
disease.
AbbVie's interferon-free regimen for the treatment of CHC includes 3 DAAs targeting 
different steps in HCV replication. Paritaprevir is a NS3/4A protease inhibitor with 
nanomolar potency in vitro and is co-administered with low-dose ritonavir, an inhibitor of 
the cytochrome P-450 enzyme CYP3A4. As a pharmacologic enhancer of paritaprevir,
ritonavir co-administration with paritaprevir (paritaprevir /r) results in higher drug 
exposures than administration of paritaprevir alone [55]. Ombitasvir (ABT-267) is a 
nonstructural protein 5A (NS5A) inhibitor with picomolar potency in vitro, and dasabuvir 
(ABT-333) is a NS5B non-nucleoside polymerase inhibitor with nanomolar potency in 
vitro.
The 3 DAA combination of paritaprevir /r – ombitasvir plus dasabuvir with or without RBV 
has been initially evaluated in 6 Phase III studies with genotype 1 infected patients

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 18 of 65
(SAPPHIRE-I [56], SAPPHIRE-II [57], PEARL-II [58], PEARL-III [59], PEARL-IV [59],
TURQUOISE-II [60]). 
Therapy for 12 weeks with the above regimen in non-cirrhotic patients resulted in the 
following SVR rates 12 weeks after EoT (SVR12):
Table 1 - SVR12 rates in clinical trials:
Population and 
treatment duration
Genotype
SVR12
ABBVIE REGIMEN + RBV
SVR12
ABBVIE REGIMEN alone
Non-cirrhotic,
treatment-naïve
(12 weeks)
1a
95-97% 
(SAPPHIRE-I, PEARL-IV)
90% 
(PEARL-IV)
1b
98-99.5%
(SAPPHIRE-I, PEARL-III)
99%
(PEARL-III)
Non-cirrhotic, 
treatment-
experienced
(12 weeks)
1a
96%
(SAPPHIRE-II)
n.a.
1b
97%
(SAPPHIRE-II, PEARL-II)
100%
(PEARL-II)
These results suggest that the ABBVIE REGIMEN with RBV is the optimal regimen for 
genotype 1a infected patients, while patients with genotype 1b do not require RBV.
The TURQUOISE-II [60] study explored the efficacy of the ABBVIE REGIMEN in the 
traditionally most difficult-to-treat cirrhotic patients. This large study enrolled exclusively
genotype 1 infected patients with cirrhosis, including treatment-naïve and treatment-
experienced individuals. All patients received the ABBVIE REGIMEN with RBV and were 
randomized to 12 or 24 weeks of therapy. Overall 92% and 96% of patients achieved 
SVR following treatment for 12 or 24 weeks, respectively. Analysis of subgroups 
demonstrated that the small difference in SVR between treatment arms was due largely 
to the subgroup of genotype 1a treatment-experienced prior null responders treated for 
12 weeks who achieved an SVR of 80%. This subgroup of patients achieved an SVR of 
93% when treated for 24 weeks. Among genotype 1a infected patients, partial 
responders and relapsers had higher SVR rates than null responders in the 12 week 
treatment group, while similar SVR rates were seen among the null responders, partial 
responders and relapsers treated for 24 weeks, suggesting that the longer duration of 24 
weeks is required only for cirrhotic genotype 1a null responders. SVR rates were very 
high across all subgroups in genotype 1b treatment-experienced patients treated for 12 
and 24 weeks. 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 19 of 65
The ABBVIE REGIMEN has been studied with and without RBV in over 2,300 patients in 
Phase III trials across a variety of patient populations including those with compensated 
cirrhosis. Based on Phase III data, the ABBVIE REGIMEN, with or without RBV, was well 
tolerated with a low discontinuation rate. Adverse events (AEs) were typically mild, and 
many of the AEs and laboratory abnormalities reported were attributable to the presence 
of RBV. However, these AEs were much milder than observed when RBV was given in 
combination with interferon. Transient, asymptomatic serum alanine aminotransferase 
(ALT) elevations were observed at a low rate, were not associated with hepatic 
dysfunction and generally resolved with ongoing treatment. A disproportionate number of 
the cases were in women on concurrent ethinyl estradiol-containing therapy (i.e., 
contraceptives or hormone replacement) and discontinuation of the hormonal therapy 
with continuation or brief interruption of the ABBVIE REGIMEN led to resolution in serum 
ALT elevation. Transient elevations in serum bilirubin (predominantly indirect) were 
observed in subjects receiving the ABBVIE REGIMEN with RBV, related to the inhibition 
of the bilirubin transporters, organic anion-transporting polypeptides (OATPs) 1B1/1B3,
by paritaprevir and RBV-induced hemolysis. Bilirubin elevations occurred after initiation 
of treatment, peaked by study Week 1, and generally resolved with ongoing therapy. 
Bilirubin elevations were not associated with aminotransferase elevations. The frequency 
of indirect bilirubin elevations was lower among subjects who did not receive RBV.
Response of CHC genotype 4 was assessed in the phase II study PEARL-I in which 86 
treatment-QDƯYH patients were randomized to the 2 DAA combination of paritaprevir/r –
ombitasvir with vs. without RBV for 12 weeks. The SVR was 100% with RBV vs. 91% 
without RBV [61]. No serious SAEs or AEs leading to discontinuation were reported.
These results from pivotal studies are encouraging and the new interferon-free regimens 
might provide physicians with the armamentarium to cure the vast majority of patients 
infected with CHC. However, the medical community is expecting data which show how
these results translate into routine clinical practice particularly after the experience with 
the first protease inhibitors which were available to physicians and where the outcome in 
everyday life and especially the tolerability was far less favorable in certain difficult-to-
treat patient subgroups than expected from the development trials [62] [63].
7.2
Rationale
The ABBVIE REGIMEN ± RBV for the treatment of CHC has been shown to be safe and 
effective in randomized controlled clinical trials with strict inclusion and exclusion criteria 
under well controlled conditions. 
The ABBVIE REGIMEN has been available in Canada for the treatment of CHC since 22 
December 2014.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 20 of 65
The rationale for this observational study is to determine how the efficacy and safety of 
the ABBVIE REGIMEN as demonstrated in pivotal trials translates into real world
everyday clinical settings, evaluating its effectiveness. Whereas efficacy can be defined 
as a measure of the capacity of a treatment to produce the desired effect in a controlled 
environment, such as in a randomized controlled trial, effectiveness is ‘the extent to 
which a drug achieves its intended effect in the usual clinical setting’ [64]. Effectiveness 
trials typically have limited exclusion criteria and will involve the broader patient 
populations in routine clinical practice, treated per local label, which might include 
patients with heterogenous compliance patterns and patients with significant comorbid 
conditions and could be used to model and disseminate best practices. Effectiveness
research allows for external patient-, provider-, and system-level factors and can 
therefore be relevant for health-care decisions by both providers in practice and policy-
makers [65].
This observational study is the first effectiveness research examining the ABBVIE 
REGIMEN ± RBV, used according to local label, under real world conditions in Canada in 
clinical practice patient population.
During the last decade when dual therapy with pegIFN plus RBV was standard of care for 
the treatment of CHC, management of patients and clinical outcome were improved 
following the discovery of predictive factors of virological response, often in observational 
studies with large data bases [66]. Thus treatment could be targeted to patients most 
likely to respond and futile treatment stopped in patients with a low likelihood of 
virological cure. HCV genotype and subtype, baseline viral load, fibrosis stage, age, 
treatment exposure and on-treatment virological response proved to be useful predictors 
for the eradication of HCV in everyday clinical practice [27]. More recently the discovery 
of a genetic disposition of the Interleukin 28B (IL28B) single nucleotide polymorphism 
(SNP) contributed further to our understanding of virological responses to treatment [67].
For new interferon-free treatment regimens knowledge of predictive factors of virological 
response is extremely sparse and several of the now well established predictors of 
response were not initially identified through analyses of the development trials. This
observational study may play an important part in bridging the data gaps and could help 
identify predictive factors of virological response in everyday clinical settings which were 
not detected in interventional trials and which could be used to further optimize treatment 
with the interferon-free ABBVIE REGIMEN in the future.
The label of the ABBVIE REGIMEN will vary according to HCV genotype/subtype and 
stage of liver disease. It is therefore relevant to understand the pattern of use and 
outcome in daily clinical practice. In addition, this study will provide data on the impact of 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 21 of 65
adherence on treatment outcomes in everyday settings, which may help treating 
physicians to improve the management of patients under their care.
The aim of this observational study is to provide evidence of the effectiveness and patient 
reported outcome (PRO) of the ABBVIE REGIMEN ± RBV and to describe work 
productivity, healthcare resource utilization and the contribution of a patient support 
program in a real world setting across clinical practice patient populations.
8.0
Research Question and Objectives
8.1
Research Question
What is the effectiveness and patient reported outcome of the interferon-free ABBVIE 
REGIMEN ± RBV in patients with CHC in a real life setting across clinical practice patient 
populations?
8.2
Objectives
Primary Objective
8.2.1
1. To describe in routine clinical practice the effectiveness of the interferon-free 
ABBVIE REGIMEN ± RBV in patients with CHC as evidenced by SVR12
Secondary Objectives
8.2.2
2. To describe the pattern of real world use of the ABBVIE REGIMEN ± RBV with 
respect to different patient and treatment characteristics 
3. To evaluate the influence of adherence on treatment outcome in routine clinical 
practice 
4. To describe the tolerability of the ABBVIE REGIMEN ± RBV
5. To document the effect of the ABBVIE REGIMEN ± RBV on PROs and work 
productivity in the Canadian population
6. To determine the impact of the ABBVIE REGIMEN ± RBV on healthcare resource 
utilization
7. To evaluate the contribution of the patient support program (PSP) to disease 
control, treatment continuation over time, patient satisfaction and PSP utilization

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 22 of 65
9.0
Research Methods
9.1
Study Design
This is a prospective, multi-center observational study in patients receiving the interferon-
free ABBVIE REGIMEN with or without RBV. The prescription of a treatment regimen is 
at the discretion of the physician in accordance with local clinical practice and label, is 
made independently from this observational study and precedes the decision to offer the 
patient the opportunity to participate in this study. 
Adult patients chronically infected with HCV, receiving the interferon-free ABBVIE 
REGIMEN will be offered the opportunity to participate in this study during a routine 
clinical visit at the participating sites.
After written patient authorization has been obtained, patient data including demographic 
data, HCV disease characteristics, co-morbidities, co-medication, treatment details, and 
laboratory assessments as recorded in the patient's medical records (source 
documentation) will be documented in the electronic case report form (eCRF). Patients
will be observed for the duration of the ABBVIE REGIMEN therapy and for up to 24 
weeks after treatment completion. No patient identifiable information will be captured, a 
unique patient number will be automatically allocated by the web based eCRF system
once the investigator or designee creates a new patient file.
This study is focusing on collecting real-world data. Follow-up visits, treatment, 
procedures and diagnostic methods will follow physicians’ routine clinical practice. The 
observational study period entails the following data collection schemes, data 
documented will be those closest to the time windows as indicated in Figure 1:
x
12-week treatment regimen: four visits plus two interim data collection windows
x
24-week treatment regimen: four visits plus three interim data collection windows
This schedule is based on the anticipated regular follow-up for patients undergoing 
treatment for CHC.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 23 of 65
Figure 1 - Study Flowchart
9.2
Setting
For overall research design and observational documentation schedule refer to Sections
9.1 and 9.4.1 as well as to Figure 1.
Target Population
9.2.1
Patients are eligible for observation in this cohort if the following applies:
x
Treatment-naïve or -experienced adult male or female patients with confirmed 
CHC, genotype 1 or 4, receiving combination therapy with the interferon-free 
ABBVIE REGIMEN ± RBV according to standard of care and in line with the 
current local label
x
If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in
line with the current local label (with special attention to contraception
requirements and contraindication during pregnancy)
x
Patients must voluntarily sign and date a patient authorization to use and/or 
disclose his/her anonymized health data prior to inclusion into the study
x
Patient must not be participating or intending to participate in a concurrent 
interventional therapeutic trial

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 24 of 65
Study Duration
9.2.2
This is a prospective, observational study. The inclusion period will be approximately 24
months and the observational period of the study will be from baseline visit until 24
weeks post-treatment.
The observational period for patients receiving 12 weeks of ABBVIE REGIMEN will be 
max. 36 weeks (12 weeks treatment and 24 weeks post-treatment observation) and for
patients receiving 24 weeks of ABBVIE REGIMEN the observational period will be max. 
48 weeks (24 weeks treatment and 24 weeks post-treatment observation).
Termination Criteria
9.2.3
For patients who terminate the ABBVIE REGIMEN prematurely for whatever reason the 
EoT eCRF page should be filled in and the reason for treatment discontinuation should 
be documented. If the reason for ABBVIE REGIMEN discontinuation is due to an SAE,
the event must be reported to AbbVie within 24 hours of physician awareness (see 
Section 11.1.5).
If, in such patients, there is evidence of virological response during therapy or at EoT, the 
SVR12 and SVR24 pages should be completed if respective data is available. 
Investigator Selection Criteria
9.2.4
University centers and outpatient clinics qualified by training and experience in the 
management of patients with CHC will be selected to participate in this study. The 
AbbVie Affiliate Medical Director will ensure that sites participating in the study are 
representative of the medical practice in the country, have the ability to conduct the study 
and their availability of the target patient population. The type of the participating treating 
institute will be documented in the eCRF.
9.3
Variables
Primary Variable
9.3.1
x
The percentage of patients achieving SVR12 (HCV RNA <50 IU/mL 12 weeks 
>LHGD\V@DIWHUWKHODVWDFWXDOGRVHRIWKHABBVIE REGIMEN)

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 25 of 65
Secondary Variables
9.3.2
x
Type of treatment regimen (± dasabuvir, ± RBV, intended and actual combination, 
dose and duration)
x
Adherence
o
Percentage of the DAA dose taken in relation to the target dose of DAA 
(cumulative dose taken divided by target dose in percent)
o
Percentage of the RBV dose taken in relation to the target dose of RBV 
(cumulative dose taken divided by target dose in percent)
o
Percentage of missed RBV treatment days in relation to the target number 
of RBV treatment days
x
Serious and non-serious adverse events and pregnancy occurrences
x
Questionnaires on PROs: EuroQol 5 dimension 5 level (EQ-5D-5L) questionnaire 
and work productivity and activity impairment (WPAI) questionnaire prior to 
treatment initiation, at EoT as well as 12 and 24 weeks after EoT
x
PAM-13, BMQ, PSP utilization and satisfaction questionnaires
9.4
Data Sources
Source documents are defined as original documents. The investigator will document 
patient data in his/her own patient files which will serve as source data for the study. Data 
are collected from the source documents for each patient in the study, consisting of 
medical records containing demographic data, medical, treatment and diagnostic
documentation and laboratory assessments.
The investigator(s)/institution(s) will permit study-related monitoring, audits, independent 
ethics committee/- review board (IEC/IRB) review, and regulatory inspection(s), providing 
direct access to source data documents.
Data to be Documented
9.4.1
This observational study covers three documentation periods, see Figure 1. An overview 
on data to be collected throughout the study is summarized in Table 2.
After the patient has signed the patient authorization form, the following data will be 
documented in the eCRF, if available from the patient charts based on assessments
done in physicians’ routine clinical practice.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 26 of 65
9.4.1.1
Inclusion Documentation
The following will be documented:
x
Demographic information
o
Interleukin 28B (IL28B) genotypes
x
CHC disease characteristics
o
Year of diagnosis and mode of infection
o
Stage of liver fibrosis
x
CHC treatment history
o
Naïve or experienced
o
If experienced, most recent prior therapy and outcome
x
Relevant medical history, co-morbidities and co-infections
x
Concomitant medication, see 9.4.1.5
x
ABBVIE REGIMEN ± RBV
x
Laboratory data
Key clinical chemistry
Remarks

ALT
(alanine-aminotransferase)
including upper limit of normal (ULN),

AST
(aspartate-aminotransferase)
including ULN, 
AST to platelet ratio index (APRI) and Fibrosis-4 Score/Index 
(FIB-4)* will be calculated 

Ȗ-GT
(gamma-glutamyltransferase)

Total bilirubin

Albumin

Creatinine

AFP
creatinine clearance# will be calculated
Key hematology

Hb (Hemoglobin)

Platelets

Prothrombin time
or international normalized ratio (INR)
Virology

HCV genotype and subtype

HCV RNA
quantitative/ qualitative HCV RNA by polymerase chain 
reaction (PCR) test, see 9.4.1.4
HIV-infected patients only

CD 4 count
(cluster of differentiation 4)
most recent assessment

HIV RNA
in copies/mL
*derived from patient’s age, ALT, AST and platelets
#by Cockcroft-Gault-Formula based on creatinine, gender, age and weight
x
PRO questionnaires, EQ-5D-5L and WPAI
x
PAM-13, BMQ
x
Treatment related health care resource utilization

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 27 of 65
9.4.1.2
During Treatment Documentation
Follow-up visits are scheduled by the physician per routine clinical practice. Likewise 
treatment, procedures and diagnostic methods will follow physicians’ routine clinical 
practice.
The following will be documented: 
x
Laboratory data
Key clinical chemistry
Remarks

ALT
including ULN

AST
including ULN, 
APRI and FIB-4 will be calculated 

Ȗ-GT

Total bilirubin

Creatinine
creatinine clearance will be calculated 
Key hematology

Hb

Platelets 
Virology

HCV RNA
quantitative/ qualitative HCV RNA PCR test, see 9.4.1.4
HIV-infected patients only

CD 4 count
most recent assessment

HIV RNA
in copies/mL
x
Concomitant medication, see 9.4.1.5
x
Adherence to ABBVIE REGIMEN ± RBV
(Subjects will maintain a daily diary to be shared with physician during visits 
[doses taken – Yes/No]. Physician will calculate the % of dose taken for ABBVIE 
Regimen and RBV. The % of dose taken for ABBVIE Regimen +/- RBV will be 
entered into the eCRF.)
x
Tolerability (SAEs and AEs, see 11.1.5) and pregnancies (see 11.1.6)
x
PRO questionnaires, EQ-5D-5L and WPAI (only at EoT/premature 
discontinuation)
x
PSP utilization and satisfaction questionnaires (at mid treatment visit of 24 weeks’ 
therapy utilization questionnaire only)
x
PAM-13, BMQ(only at EoT/premature discontinuation)
x
Treatment related health care resource utilization
9.4.1.3
Post-Treatment Documentation
Follow-up visits are scheduled by the physician per routine clinical practice. Likewise 
treatment, procedures and diagnostic methods will follow physicians’ routine clinical 
practice.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 28 of 65
The following will be documented: 
x
Laboratory data
Key clinical chemistry
Remarks

ALT
including ULN

AST
including ULN, 
APRI and FIB-4, will be calculated 

Ȗ-GT

Total bilirubin

Albumin

Creatinine
creatinine clearance will be calculated 
Key hematology

Hb

Platelets

Prothrombin time
or INR
Virology

HCV RNA
quantitative/ qualitative HCV RNA PCR test, see 9.4.1.4
HIV-infected patients only

CD 4 count
most recent assessment

HIV RNA
in copies/mL
x
Tolerability (SAEs, see 11.1.4) and pregnancies (see 11.1.6)
x
PRO questionnaires, EQ-5D-5L and WPAI (12 and 24 weeks after EoT)
x
PSP utilization and satisfaction questionnaires (at early post-treatment visit 
utilization questionnaire only) 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 30 of 65
9.4.1.4
HCV RNA Sample
HCV RNA sample – the following needs to be documented:
x
Quantitative HCV RNA by PCR test 
o
Test name and result in IU/mL
o
Lower limit of detection (LLoD) in IU/mL and lower limit of quantification 
(LLoQ) in IU/mL
x
Qualitative HCV RNA by PCR test 
o
Test name and result (positive/negative)
o
LLoD in IU/mL
9.4.1.5
Concomitant Medication 
Concomitant medication - the following will be documented:
x
Concomitant medication used from the time when the decision is made to initiate 
treatment with the ABBVIE REGIMEN until after the last dose
It should be verified by the treating physician that concomitant medication can be safely 
administered with the ABBVIE REGIMEN (including ritonavir) and RBV. Some 
medications may be contra-indicated, some may require dose adjustments due to 
potential for drug-drug interactions (DDIs). The investigator or qualified designee should 
review the concomitant medication(s) labels and screen concomitant medications at each 
visit for potential DDIs.
9.4.1.6
Standardized Assessment Tools
This study will assess quality of life and work productivity using PRO instruments: EQ-
5D-5L and WPAI Hep C. Validated translations of these patient questionnaires will be 
administered.
Assessment of general quality of life - EQ-5D-5L
The EQ-5D-5L is a health state utility instrument that evaluates preference for health 
status (utility). The 5 items in the EQ-5D-5L comprise 5 dimensions (mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression) each of which are rated on 5 
levels of severity. Responses to the 5 items encode a discrete health state which is 
mapped to a preference (utility) specific for different societies. Patients also rate their 
perception of their overall health on a separate visual analogue scale (VAS). 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 31 of 65
The EQ-5D-5L should require approximately 5 minutes to complete and is presented in 
Annex 1.
Assessment of work productivity and activity impairment – WPAI Hep C V2.0
The WPAI questionnaire will be used to measure work absenteeism, work presenteeism, 
and daily activity impairment. The WPAI questionnaire was created as a patient-reported 
quantitative assessment of both reduced productivity at work and non-work activities. 
WPAI has been validated as a general health measure (WPAI-GH) and can be easily 
modified for specific health condition, disease or problem (WPAI-SHP). WPAI Hep C 
V2.0 is the HCV specific questionnaire that will be used in this study). Respondents are 
asked about time missed from work and time while at work during which productivity was 
impaired in the past seven days. Results of WPAI are expressed as a percentage of 
impairment from 0 to 100, with higher percentages indicating greater impairment and less 
productivity: 
x
% Presenteeism – percentage of impairment while working due to health problem
x
% Absenteeism – percentage of work time missed due to health problem
x
% Total work productivity impairment (TWP) – percentage of overall work 
impairment due to health problem
x
% Total activity impairment (TAI) – percentage of general (non-work) activity 
impairment due to health problem
The WPAI Hep C should require approximately 5 minutes to complete and is presented
in Annex 2.
PRO data are not considered a potential source of adverse reactions. However, 
participating sites should review the PRO data and if a possible product-related event 
(including a suspected adverse reaction) is noted, the health care provider (HCP) must 
determine whether the event is related to paritaprevir/r – ombitasvir ± dasabuvir (or any 
other AbbVie authorized product) and if so, it should be reported to AbbVie. The relevant 
AbbVie Pharmacovigilance contact details are specified in Section 11.0.
Patient Activation Measure – (PAM)
PAM-13 is a measure used to assess the patient knowledge, skill, and confidence for 
self-management. It should require approximately 7 minutes to complete and is 
presented in Annex 3.
Beliefs Medication Questionnaire – (18-item BMQ)

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 32 of 65
The 18-item BMQ consists of 18 questions used to screen for patients’ beliefs, attitudes 
and concerns about their medication. 
The BMQ should require approximately 10 minutes to complete and is presented in 
Annex 4.
Patient Support Program (PSP) Questionnaires
The PSP utilization and satisfaction assessment will evaluate the frequency of utilization 
and patient’s overall satisfaction with their respective Patient Support Program.
The PSP questionnaires should require approximately 2-5 minutes to complete and are
presented in Annex 5-6.
9.5
Study Size
In phase III studies investigating the interferon-free ABBVIE REGIMEN ± RBV, SVR12 
rates of at least 90% were observed, even in difficult-to-treat CHC patients (e.g. cirrhotic 
G1a treatment experienced patients). To describe in routine clinical practice the 
effectiveness of the ABBVIE REGIMEN ± RBV in patients with CHC, a precise estimate 
of the SVR12 rates in the core population of this study should be achieved (see Section
9.7.1 for the definition of the core population).
It is expected, that during the planned inclusion period of 24 months about 600 – 800 
patients treated with the ABBVIE REGIMEN ± RBV can be included into this 
observational study, and that almost all patients will be evaluable in the core population.
As obvious from Table 3, if the SVR12 rate is at least 90%, then with 800 patients the 
width of the 95% confidence interval (CI) will not be wider than 3.2%. Even in the case 
that fewer patients will be enrolled and only 600 patients can be evaluated in the core
population, the 95% CI will have a width of less than 5% for a SVR12 rate of at least 90% 
and less than 4% for a SVR12 rate of at least 95%.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 33 of 65
Table 3
Width of 95% Confidence Interval for SVR12
Number of
patients
SVR12 rates
95% Confidence Interval*
Lower Limit
Upper Limit
Width 
800
95%
93.25
96.40
3.15%
800
90%
87.71
91.99
4.28%
700
95%
93.12
96.49
3.38%
700
90%
87.54
92.12
4.59%
600
95%
92.94
96.60
3.66%
600
90%
87.32
92.28
4.97%
* exact two-sided 95% confidence interval according Clopper-Pearson
Assuming, that in total 800 patients can be enrolled, and larger subgroups consist of at 
least 25% of the entire group (i.HSDWLHQWVWKHQWKHZLGWKRIWKH&,ZLOO be
IRUD695UDWHRIDQGIRUD695UDWHRIZKLFKLVDOVR
considered sufficiently precise for subgroup analyses.
9.6
Data Management
Electronic Case Report Forms
9.6.1
Data for this study will be recorded in English by each participating center via an 
electronic data capture (EDC) system using a web-based eCRF. Examinations, 
diagnostic measures, laboratory assessments, findings and observations routinely 
performed in patients with CHC included in this cohort, will be transcribed by the 
investigator or designee from the source documents into the eCRF. Only data specified 
in the protocol will be entered into the eCRF. For each enrolled patient, the investigator 
or designee will create a new patient file in the eCRF and a unique patient number will be 
automatically allocated by the system.
A comprehensive data validation program utilizing front-end checks in the eCRF will 
validate the data. Automated checks for data consistency will be implemented, 
discrepancies need to be solved by the researcher in the eCRF before the module can 
be completed. 
Follow-up on eCRF data for medical plausibility will be done by AbbVie personnel (or 
their representatives). Queries will be generated in the eCRF for online resolution at the 
site. The investigator or an authorized member of the investigator's staff will make any 
necessary data corrections to the eCRF. All change information, including the date and 
person performing the corrections, will be available via the audit trail, which is part of the 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 34 of 65
EDC system. The principal investigator of each site will finally review the eCRFs for 
completeness and accuracy of available data and provide his or her electronic signature 
and date to the eCRFs as evidence thereof. 
Access to the EDC system will be provided for the duration of the study through a 
password-protected method of internet access. Such access will be removed from 
investigator sites at the end of the site's participation in the study. Data from the EDC 
system will be archived on appropriate data media (e.g. CD-ROM) and provided to the 
investigator as a durable record of the site's eCRF data.  
Handling of Questionnaires
9.6.2
For data entry at the CRO, completed questionnaires will sent by the sites by fax or as 
scan via email to the address below:
Prior to sending the questionnaires, sites should make sure that the correct unique 
patient number is entered on the questionnaires, the pertinent visit is indicated and that 
no patient identifiable information (e.g. name or signature) is captured on the form. 
If there are any issues in forwarding the questionnaires to
 (e.g. 
international fax line not available, no scanner), sites should contact their site monitor in 
order to obtain shipping instructions.
Assignment of Preferred Terms
9.6.3
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and 
will be tabulated by primary MedDRA system organ class (SOC) and preferred term (PT).
For treatments, surgical and medical procedures the international non-proprietary name 
(INN) Drug Terms and Procedures Dictionary will be used.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 35 of 65
9.7
Data Analysis
Analysis Population, Time Windows and Handling of 
9.7.1
Missing Data 
The target population (TP) is defined as all patients who fulfill the criteria specified in 
Section 9.2.1. The core population (CP) is defined as all patients of the TP, who have 
started the treatment combination recommended in the current local label for their 
disease characteristics. Patients not receiving the treatment recommended in the local 
label will be summarized in the non-core population (NCP). In addition, the core 
population with sufficient follow-up data (CPSFU) is defined as all CP patients, who fulfil 
one of the following criteria: 
(1) HYDOXDEOH+&951$GDWDGD\VDIWHUWKHODVWDFWXDOGRVHRIWKHABBVIE 
REGIMEN (i.e. data within the SVR12 time window)
(2) D+&951$YDOXH50 IU/mL at the last measurement post-baseline (i.e. no
virological response achieved at the last measurement on-treatment or post-
treatment)
(3) HCV RNA <50 IU/mL at the last measurement post-baseline, but no HCV RNA 
PHDVXUHPHQWGD\VDIWHUWKHODVWDFWXDOGRVHRIWKHABBVIE REGIMEN due
to reasons related to safety (e.g. dropped out due to AE) or incomplete efficacy 
information (e.g. virologic failure such as relapse is reported in the eCRF but date 
and value of the corresponding HCV RNA test is missing). This means only 
patients who had virological response at their last on-treatment or post-treatment 
measurement, buWKDGQR+&951$PHDVXUHPHQWV70 days post-treatment for 
reasons not related to safety or effectiveness (e.g. lost-to-follow-up or patient not 
willing to perform an additional HCV RNA test 70 days post-treatment) will be 
excluded from this analysis.
The Safety Population (SP) is defined as all patients who received at least one dose of 
the ABBVIE REGIMEN.
In accordance with the non-interventional nature of the study all HCV RNA 
measurements will be performed at the sole discretion of the physician and all HCV RNA 
measurements have to be entered into the eCRF. All recorded HCV RNA values will be 
assigned to appropriate time points (baseline, on-treatment visits, EoT visit, post-
treatment visits). The time windows for the assignments will be specified in the statistical 
analysis plan (SAP).

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 36 of 65
No data will be imputed for any effectiveness or safety analyses except for the analyses 
of the HCV RNA endpoints. When there is no HCV RNA value in a visit time window 
post-baseline, but prior to EoT, the closest values before and after the window, 
regardless of the value chosen for the subsequent and preceding window, will be used 
for the flanking imputation described below. If a patient has a missing HCV RNA value at 
a post-baseline visit prior to EoT but has undetectable HCV RNA (with LLoD 50 IU/mL) 
or unquantifiable, but detectable HCV RNA levels (with LLoQ 50 IU/mL) at both the 
preceding and succeeding measurements, the HCV RNA level will be considered 
undetectable or unquantifiable, respectively, at this visit for this patient. In addition, if a 
patient has an unquantifiable HCV RNA level at the preceding measurement and an 
undetectable HCV RNA level at the succeeding measurement, or vice versa, the HCV
RNA level will be imputed as unquantifiable at this visit for this patient. For virological 
response at EoT a corresponding backward imputation approach will be applied. This 
means if HCV RNA is missing at EoT, then unquantifiable or undetectable will be 
assumed for EoT, if the succeeding HCV RNA value is undetectable or unquantifiable. 
For SVR12 the single last available HCV RNA mHDVXUHPHQW70 days post-treatment will 
be used. Subsequent to this flanking and backward imputation, if the HCV RNA value 
remains missing at a specific time point, then the patients will considered as virological 
failure at this time point (i.e. not undetectable or unquantifiable).
Demographics and Disease Characteristics 
9.7.2
All baseline and disease characteristics will be summarized for the CP stratified by the 
CP analysis groups (i.e. based on genotype 1 subtype, fibrosis status, treatment 
experienced or QDƯYH), which are relevant for scheduled treatment combination (ABBVIE 
REGIMEN ± RBV) and duration (12 and 24 weeks). In addition, baseline summaries will 
be repeated for the SP and the TP without stratification into subgroups. Summary 
statistics (n, mean, median, standard deviation [SD], and range) will be generated for 
continuous variables (e.g. age and body mass index [BMI]). The number and percentage 
of patients will be presented for categorical variables (e.g. gender and race). Further 
details of analysis populations and the CP analysis groups will be specified in the SAP, 
taking into account the ABBVIE REGIMEN recommended in the current local label for 
various patient groups.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 37 of 65
Effectiveness Analysis
9.7.3
The primary effectiveness analysis on clinical outcomes will be performed on all patients 
in the CP stratified by the CP analysis groups. Due to the non-interventional nature of this 
study several different methods for determination of the HCV RNA value can be applied. 
)RUWKHSXUSRVHRIWKHVWDWLVWLFDODQDO\VLVD+&951$PHDVXUHPHQWLVFRQVLGHUHG
IU/mL,
•
if a PCR test was used
•
and the test result is undetectable and WKH//R'RIWKHWHVWLV,8P/RUWKH
WHVWUHVXOWLVXQTXDQWLILDEOHDQGWKH//R4LV,8P/
9.7.3.1
Primary Effectiveness Endpoint
The percentage of patients achieving SVR12 (single last HCV RNA <50 IU/mL 12 weeks
[i.e. at least 70 days] after the last actual dose of the ABBVIE REGIMEN) is the primary 
effectiveness endpoint.
9.7.3.2
Secondary Effectiveness Endpoints
The following secondary effectiveness endpoints will be determined in addition to the 
primary effectiveness endpoint SVR 12:
x
The percentage of patients with virological response (HCV RNA <50 IU/mL) at 
EoT
x
The percentage of patients with relapse (defined as HCV RNA <50 IU/mL at 
EoT followed by HCV RNA 50 IU/mL)
x
The percentage of patients with breakthrough (defined as at least one 
documented HCV RNA <50 IU/mL followed by HCV RNA 50 IU/mL during 
treatment). 
x
The number and percentage of patients meeting each and any of the following 
SVR12 non-response categories:
o
On-treatment virologic failure (breakthrough [defined as above ] or 
failure to suppress [each measured on-treaWPHQW+&951$YDOXH50
IU/mL])
o
Relapse (defined as HCV RNA <50 IU/mL at EoT or at the last on-
WUHDWPHQW+&951$PHDVXUHPHQWIROORZHGE\+&951$50 IU/mL
post-treatment)

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 38 of 65
o
Premature study drug discontinuation with no on-treatment virologic 
failure
o
Missing SVR12 data and/or none of the above criteria
9.7.3.3
Statistical Methods for Analysis of Effectiveness Variables
The simple percentage of patients achieving SVR12 will be calculated and an exact two-
sided 95% confidence interval (CI) of the percentage will be computed based on the
Clopper-Pearson method.
Corresponding methods will be used for other response rates (EoT response rate,
relapse rate, viral breakthrough). The relapse rates will be estimated in patients of the CP
analysis groups with EoT response and sufficient HCV RNA measurements post-
treatment. Viral breakthrough rates will be estimated in all patients of the CP analysis 
groups, who have at least one undetectable HCV RNA measurement on-treatment and at 
least one on-treatment or EoT measurement thereafter. 
Univariate and multiple logistic regression (MLR) methods will be used to investigate the 
impact of the following explanatory covariates on SVR12:
x
Key demographic information
x
Mode of CHC infection
x
HCV RNA level at baseline
x
Most recent stage of liver fibrosis
x
HCV genotype and subtype (if available)
x
Type of treating institute
x
Liver and/or CHC related co-morbidities
x
Key clinical chemistry and hematology laboratory variables at baseline 
x
In treatment experienced patients only: 
o
Most recent prior treatment for CHC
o
Outcome of most recent prior CHC treatment
Further details and additional covariates will be specified in the SAP.
These analyses will be of exploratory nature, data driven, and will be repeatedly 
performed for various CP Analysis Groups, since not each covariate might be predictive 
in each patient group. Furthermore, the fact that treatment regimens will differ in the
various patient groups has to be taken into account, when selecting the patient groups for 
each MLR analysis. Backward selection procedures will be applied to generate the final 
MLR models which consider only covariates in the selection procedure with a p-value 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 39 of 65
<0.25 in the corresponding univariate logistic regression analysis. A p-value <0.05 will be 
used for the covariates to stay in the model in a backward elimination step. Logistic 
regression methods will also be used to investigate the impact of treatment adherence on 
SVR12. 
Clinical Laboratory Data
9.7.4
All reported clinical laboratory test results will be assigned to one of the time points using 
the time windows specified in the table below.
Table 4 - Analysis Time Windows
Phase
Time point
Time Window
Pre-Treatment
Baseline
Last value prior to start of study treatment 
(i.e. dstudy day 1)
Study day during treatment period
(Study day 1 = first treatment day)
Treatment Weeks
4 (day 29)
15 - 42
8 (day 57)
43 - 70
12 (day 85)
71 - 98
16 (day 113)
99 - 126
EoT 
Actual EoT
Study day of last dose
(14 days prior to EoT - 14 days post EoT)
Post Treatment 
4 weeks
(day 29 post EoT)
15 – 56 post EoT
12 weeks 
(day 85 post EoT)
57 – 112 post EoT
24 weeks
(day 169 post EoT)
141 – 196 post EoT
Mean changes from baseline to each post-baseline visit will be summarized descriptively.
Laboratory data values collected during the treatment period will be categorized as low, 
normal, or high based on reference ranges used in this study. The number and percent of 
patients who experience post-baseline shifts during treatment in clinical laboratory values 
from low/normal to high and high/normal to low based on the reference range will be 
summarized.
Additional details of the analyses of clinical laboratory data will be specified in the SAP.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 40 of 65
PRO Questionnaires
9.7.5
The EQ-5D-5L is a health state utility instrument that evaluates preference for health 
status (utility). The EQ-5D-5L comprises 5 dimensions (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression) each of which are rated on 5 levels of 
severity (1: indicating no problem, 2: indicating slight problems, 3: indicating moderate 
problems, 4: indicating severe problems, 5: indicating extreme problems), and a separate 
VAS.
Patients’ responses to the EQ-5D-5L will be combined into a unique health state using a 
5-digit code with one digit from each of the 5 dimensions representing the level of 
severity. These EQ-5D-5L states will be converted into a single preference-weighted 
health utility index score by applying country-specific weights (if available) or US weights 
(if not available).
No imputation will be performed for missing items, and in case of missing items no index 
score will be calculated. 
A summary table will show descriptive statistics (n, mean, median, SD, minimum and 
maximum) of the index score values and for the VAS values for baseline and the post-
baseline time points, as well as changes from baseline both for the index score values 
and for the VAS values. In addition analysis of covariance (ANCOVA) will be applied to 
investigate the effect of the different ABBVIE REGIMENS (± RBV and duration) on EQ-
5D-5L endpoints using the corresponding EQ-5D-5L baseline values as covariates.
Further details will be specified in the SAP.
Assessments of work productivity and activity impairment as assessed by the WPAI Hep 
C v2.0 will be evaluated according to the WPAI-SHP scoring manual. The WPAI yields 
four types of scores, the results of which will be presented as percentage of impairment 
from 0 to 100. Higher percentages indicate greater impairment:
1. % absenteeism: percentage of work time missed due to hepatitis C
2. % presenteeism: percentage of impairment while working due to hepatitis C
3. % TWP: percentage of overall work impairment due to hepatitis C
4. % TAI: percentage of general (non-work) activity impairment due to hepatitis C
The WPAI Hep C v2.0 consists of 6 questions aimed at the following targets:
Q1. currently employed (yes, no)
Q2. hours missed due to hepatitis C in the last seven days
Q3. hours missed due to other reasons in the last seven days
Q4. hours actually worked in the last seven days

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 41 of 65
Q5. degree hepatitis C affected productivity while working
Q6. degree hepatitis C affected regular activities
The four scores will be derived as follows:
1. % absenteeism:
100*Q2/(Q2+Q4)
2. % presenteeism:
100*Q5/10
3. % TWP:
100*{Q2/(Q2+Q4) + [Q4/(Q2+Q4)]* Q5/10}
4. % TAI:
100*Q6/10
A score will be set to missing if one or more of the items Q1-Q6 that are needed for the 
calculation of the score are missing. No imputation will be performed for missing items.
The summary table will present the absolute and relative frequencies of employed and 
unemployed patients and descriptive statistics for the four scores. Further details of the 
analysis will be specified in the SAP.
PSP, PAM and BMQ
9.7.6
The contribution of the patient support program (PSP) to disease control, treatment 
continuation over time, patient satisfaction and PSP utilization will be analyzed using 
descriptive and exploratory statistical methods. Appropriate frequency tables will 
summarize all corresponding variables of the PSP questionnaires (see ANNEX 5 and 6)
over time stratified by ABBVIE REGIMEN arms. In addition, multiple logistic regression 
(MLR) analysis will be performed to investigate the association between the use of the 
PSP, the patient satisfaction variables of the PSP questionnaires with the probability to 
treatment completion. These MLRs will be performed similar to the MLRs for SVR12 (see 
Section 9.7.3.3). Additional details will be specified in the SAP.
The Patient Activation Measure (PAM) 13 item scale is a measure used to assess the 
patient knowledge, skill, and confidence for self-management. Each of the 13 items can 
be answered with one of four possible response options, which are “disagree strongly” 
(1), “disagree” (2), “agree” (3), “agree strongly” (4). 
Based on responses to the 13-item measure, the score is calculated by adding up the 
raw scores (range of the sum: 13 – 52) and mapping up the value onto a scale of 0–100 
indicating strength of agreement with the 13 items (100 *(sum - 13) / (52 - 13)).The final 
score can be assigned to one of the four levels of activation. A higher score indicates that 
the patient is likely to participate more actively in health care processes and takes more 
responsibility for his or her health.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 42 of 65
In case of missing item values, the mean value of the available items will be used for 
replacement. However, if there are less than nine items answered, no summary score will 
be calculated.
The same statistical methods as specified above for EQ-5D-5L will be applied for the 
PAM summary score.
The 18-item Beliefs Medication Questionnaire (BMQ) consists of 18 questions used to 
screen for patients’ beliefs, attitudes and concerns about their medication. The 18 items 
are rated on a Likert scale from 1=strongly disagree to 5 = strongly agree and the 18 
items are summarized into 4 scale scores: necessity of their medication, medication-
related concerns, general medication-related harm and general medication overuse. The 
total score of each BMQ subscale will be calculated.
The same statistical methods as specified above for EQ-5D-5L will be applied for the 
BMQ subscales.
Resource Utilization
9.7.7
Data of resource utilization will be captured separately with regard to outpatient 
consultation and hospitalizations. Descriptive analysis will be used to present the data on 
resource utilization. Further details will be specified in the SAP.
Tolerability Analysis
9.7.8
All tolerability variables will be summarized using descriptive statistical methods for the 
SP stratified by type of combination treatment and scheduled treatment duration.
All SAEs, non-serious AEs and pregnancy occurrences are to be reported for patients
included in the study (see Section 11.0). AEs will be coded using MedDRA. The number 
and percentage of patients with treatment-emergent AEs (i.e. any reported event that 
begins or worsens in severity after initiation of study drug through 30 days post-study 
drug dosing) will be tabulated by primary MedDRA SOC and PT. Corresponding 
summary tables will be provided for all serious treatment-emergent AEs. The tabulation 
of the number of patients with treatment-emergent AEs by severity and relationship to 
study drug will also be provided. Patients reporting more than one AE for a given 
MedDRA PT will be counted only once for that term using the most severe incident for 
the severity summary table and the most related for the relationship summary table. 
Patients reporting more than one type of event within a SOC will be counted only once 
for that SOC.
Additional details of the analysis of AEs will be specified in the SAP. 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 43 of 65
Interim Assessments
9.7.9
Three interim assessments are planned. The first interim analysis will be done with a 
data cut-off February 29th, 2016. Once the data is sufficiently cleaned it will be used for 
analysis regarding baseline characteristics of the patients and planned treatment 
regimen.
The second (third) interim analysis will be performed as soon as the first 200 (400) 
enrolled and treated patients have
(1) their treatment period completed,
(2) are evaluable regarding SVR12 (or dropped out early for any reason and no HCV 
RNA are available in the SVR12 time window or relapsed prior to the SVR12 time 
window)
(3) and the data of these patients are sufficiently cleaned.
Further details of the interim analyses will be specified in the SAP.
9.8
Quality Control
The sites will be instructed in the protocol, the functionality and handling of the eCRF,
and the requirement to maintain source documents for each patient in the study (see 
Section 9.4).
A comprehensive data validation program utilizing front-end checks in the eCRF will 
validate the data. Automated checks for data consistency will be implemented, 
discrepancies need to be solved by the researcher in the eCRF before the module can 
be completed. Follow-up on eCRF data for medical plausibility will be done by AbbVie 
personnel (or their representatives). The principal investigator of each site will finally 
review the eCRFs for completeness and accuracy of available data and provide his or 
her electronic signature and date to eCRFs as evidence thereof.
Continuous monitoring of the study and frequent site telephone contacts will be done by 
AbbVie or a CRO working on behalf of AbbVie.
9.9
Limitations of the Research Methods
The limitations of observational studies, such as uncontrolled confounding by lack of 
randomization, and difficulties to clearly interpret treatment effects in the context of 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 44 of 65
missing data are well known. Their validity can be increased by accurate outcome 
measurements, documentation of the most common confounders, sufficient length of 
follow-up and by activities to obtain complete recording of available data as well as by 
searches for missing key data. 
The most important outcome measure in this study is HCV RNA. Missing or unrecorded 
follow-up HCV RNA data can in particular lead to an underestimation of the real SVR rate 
as compared to the SVR rate of interventional trials. Highly sensitive and quantitative 
diagnostic tests are required to measure HCV RNA levels in blood. In an observational 
study each center will be using its own test – either commercially available or so-called
“home-brew” tests – which might change from one visit to the next within a patient data 
set. The challenge is to accurately and consistently document test properties such as the
LLoD and the LLoQ to put the results into perspective of prior outcomes from randomized 
controlled trials with (usually) central laboratory assessments for all trial participants.
10.0
Protection of Human Subjects
This observational study will be run in compliance with local laws and regulations. 
Notification/submission to the responsible regulatory authorities, Ethics Committee (EC) 
and/or Competent Authorities (CAs) will be done as required by local laws and 
regulations.
The investigator is responsible to ensure that written patient authorization to use and/or 
disclose patients’ anonymized health data will be obtained prior to patient inclusion 
To maintain patient confidentiality, no demographic data that can identify the patient will 
be collected (e.g. initials, date of birth) - only the patient age will be collected. In order to 
protect patient identity, a unique number will be assigned to each patient and related
study recording.
11.0
Management and Reporting of Complaints
A Complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the physical characteristics, identity, quality, purity, potency, durability, 
reliability, safety, effectiveness, or performance of a product/device after it is released for 
distribution.
Complaints associated with any component of the ABBVIE REGIMEN must be reported 
to the Sponsor (Section 11.2.2).

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 45 of 65
For adverse events, please refer to Sections 11.1.1 through 11.1.7. For product 
complaints, please refer to Section 11.2. 
11.1
Medical Complaints
PRO data are not considered a potential source of adverse reactions. However, 
participating sites should review the PRO data and if a possible product-related event 
(including a suspected adverse reaction) is noted, the HCP must determine whether the 
event is related to the ABBVIE REGIMEN ± RBV (or any other AbbVie authorized 
product) and if so, it should be reported to AbbVie. 
Medication errors (this refers to any unintentional error in the prescribing, dispensing, or 
administration of a medicinal product while in control of the HCP, patient or consumer) 
should be reported by the HCP to AbbVie.
The relevant AbbVie contact details are specified below: 
Adverse Event Definition and Serious Adverse Event 
11.1.1
Categories
An adverse event (AE) is defined as any untoward medical occurrence in a patient, which 
does not necessarily have a causal relationship with their treatment. An AE can therefore 
be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, whether 
or not the event is considered causally related to the use of the product.
Such an event can result from use of the drug as stipulated in the labeling, as well as 
from accidental or intentional overdose, drug abuse, or drug withdrawal. Any worsening 
of a pre-existing condition or illness is considered an AE. 
If an AE meets any of the following criteria, it is considered a serious adverse event 
(SAE):
Death of Patient:
An event that results in the death of a patient.
Life-Threatening:
An event that, in the opinion of the investigator, would 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 46 of 65
have resulted in immediate fatality if medical 
intervention had not been taken. This does not 
include an event that would have been fatal if it had 
occurred in a more severe form.
Hospitalization:
An event that results in an admission to the hospital 
for any length of time. This does not include an 
emergency room visit or admission to an outpatient 
facility.
Prolongation of 
Hospitalization:
An event that occurs while the study patient is 
hospitalized and prolongs the patient's hospital stay.
Congenital Anomaly:
An anomaly detected at or after birth, or any anomaly 
that results in fetal loss.
Persistent or Significant 
Disability/Incapacity:
An event that results in a condition that substantially 
interferes with the activities of daily living of a study 
patient. Disability is not intended to include 
experiences of relatively minor medical significance 
such as headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g. sprained 
ankle).
Important Medical Event 
Requiring Medical or 
Surgical Intervention to 
Prevent Serious Outcome:
An important medical event that may not be 
immediately life-threatening or result in death or 
hospitalization, but based on medical judgment may 
jeopardize the patient and may require medical or 
surgical intervention to prevent any of the outcomes 
listed above (i.e. death of patient, life threatening, 
hospitalization, prolongation of hospitalization, 
congenital anomaly, or persistent or significant 
disability/incapacity). Additionally, any elective or 
spontaneous abortion or stillbirth is considered an
important medical event. Examples of such events 
include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug 
dependency or drug abuse.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 47 of 65
Severity
11.1.2
The following definitions will be used to rate the severity for any AE being collected as an 
endpoint/data point in the study and for all SAEs.
Mild:
The AE is transient and easily tolerated by the patient.
Moderate:
The AE causes the patient discomfort and interrupts the patient's 
usual activities.
Severe:
The AE causes considerable interference with the patient's usual 
activities and may be incapacitating or life threatening.
Relationship to Pharmaceutical Product
11.1.3
The following definitions will be used to assess the relationship of the AE to the use of 
product:
Reasonable Possibility
An AE where there is evidence to suggest a causal 
relationship between the product and the AE.
No Reasonable 
Possibility
An AE where there is no evidence to suggest a causal 
relationship between the product and the AE.
If no reasonable possibility of being related to product is given, an alternate etiology must 
be provided for the AE.
Serious Adverse Event Collection Period
11.1.4
SAEs will be reported to AbbVie from the time the physician obtains the patient's 
authorization to use and disclose information until 30 days or 5 half-lives following the 
intake of the last dose of physician-prescribed treatment.
Serious and non-serious Adverse Event Reporting
11.1.5
In the event of an SAE, the physician will:
Ɣ
For events from patients using the ABBVIE REGIMEN ± RBV (or any other 
AbbVie authorized product) report to AbbVie within 24 hours of the physician 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 48 of 65
becoming aware of the event by using the eCRF system or notifying the
AbbVie contact information identified in Section 11.1.
Ɣ
For events from patients using a non-AbbVie product - notify the Marketing 
Authorization Holder (MAH) of the product within 24 hours of the physician 
becoming aware of the event.
In the event of a non-serious AE, the physician will: 
Ɣ
For events from patients using the ABBVIE REGIMEN ± RBV report to AbbVie 
by using the eCRF system. 
Pregnancy Reporting
11.1.6
Patients and their partners should avoid pregnancy and males should avoid sperm 
donation throughout the course of the HCV treatment and for 30 days after the end of 
treatment with DAAs only, or for 7 months after the last dose of RBV (or per local RBV 
label) and/or consistent with local treatment guidelines for RBV.
In the event of a pregnancy occurrence in the patient, the physician will report to AbbVie 
within 24 hours of the physician becoming aware of the pregnancy by using the eCRF 
system or notifying the AbbVie contact information identified in Section 11.1.
Unusual Failure in Efficacy
11.1.7
Lack of efficacy is the failure of a health product to produce the expected intended 
benefit. The Canadian Food and Drug Act and Regulations require that manufacturers 
report cases of unusual failure in efficacy to Health Canada for new drugs in the post-
marketing setting, including in Phase IV studies. 
Physicians should exercise clinical judgment to determine if the lack of efficacy is related 
to the drug itself, rather than one of treatment selection or disease progression since 
health products cannot be expected to be effective in 100% of the patients.
The Investigator shall report all cases of unusual failure in efficacy coincident with the 
use of the study drug to AbbVie within 24 hours by using the eCRF system or notifying 
the AbbVie contact information identified in Section 11.1.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 49 of 65
11.2
Product Complaint
Definition
11.2.1
A Product Complaint is any Complaint (see Section 11.0 for the definition) related to the 
drug or drug component of the product.
For a product this may include, but is not limited to, damaged/broken product or 
packaging, product appearance whose color/markings do not match the labeling, labeling 
discrepancies/inadequacies in the labeling/instructions (example:  printing illegible), 
missing components/product, or packaging issues.
Reporting
11.2.2
Product Complaints concerning ABBVIE REGIMEN are reported by patients through their 
Patient Support Program as per local process. In the rare event that a product complaint 
is not reported by the patient but reported to the site, the site must report to the Sponsor 
within 24 hours of the study site’s knowledge of the event as per AbbVie local Product 
Complaint reporting practices, at the following telephone number: Consumer Relations 
Tel: 1- 888-704-8271. Product Complaints occurring during the study will be followed-up
to a satisfactory conclusion by AbbVie as per the local Product Complaint reporting 
practices. Initial and all follow-up information is to be reported to AbbVie and 
documented in source as required by the Sponsor. All other complaints will be monitored 
on an ongoing basis by AbbVie as per usual practices. Product complaints involving a 
non-Sponsor medicinal product and/or device should be reported to the identified contact 
or manufacturer, as necessary per local regulations. Product Complaints may require 
return of the product with the alleged complaint condition. In instances where a return is 
requested, AbbVie Consumer Relations will manage return of the product as per their 
standard process. The description of the complaint is important for AbbVie in order to 
enable AbbVie to investigate and determine if any corrective actions are required.
12.0
Plans for Disseminating and Communicating Study 
Results
At the end of this observational study, a report will be written by AbbVie or a CRO 
working on behalf of AbbVie. The required standard study report template will be 
followed. This report will contain a description of the objectives of the study, the 
methodology and its results and conclusions. The completed eCRFs, patient 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 50 of 65
questionnaires, interim assessments, the final study output and study report are the 
confidential property of AbbVie and may not be released to unauthorized people in any 
form (publications or presentations) without express written approval from AbbVie. The 
study results will be submitted to local authorities by the participating countries per local 
laws and regulations.
The results of this study will be made publicly available on one of the primary registries in 
the World Health Organization (WHO) Registry Network which meet the requirements of 
the ICMJE (International Committee of Medical Journal Editors) and through scientific 
publications. Authorship will be in line with ICMJE’ authorship requirements [68].

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 51 of 65
13.0
References
[1]
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the 
Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
[2]
Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) Infection. Int J 
Med Sci 2006; 3: 47-52.
[3]
Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 (Suppl 1):
S21-9.
[4]
Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management.
Hepatology 2000; 31: 1014-8.
[5]
Pawlotsky JM. Hepatitis C virus: from discovery to eradication in 40 years? Clin 
Microbiol Infect 2011; 17: 105-6.
[6]
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 
107-15.
[7]
WHO. Weekly epidemiological record. 2000; 75, 17-28. Available at 
http://www.who.int/docstore/wer/pdf/2000/wer7503.pdf.
[8]
Szabo SM, Bibby M, Yuan Y et al. The epidemiologic burden of hepatitis C virus 
infection in Latin America. Ann Hepatol 2012; 11: 623-35.
[9]
Pereira LMMB, Martelli CMT, Moreira RC et al. Prevalence and risk factors of hepatitis 
C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis 
2013; 13: 1-12.
[10]
Eurosurveillance 2003; 8 (5): 99-118.
[11]
Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7
genotypes and 67 subtypes: updated criteria and genotype assignment web resource.
Hepatology 2014; 59: 318-27.
[12]
US Department of Health and Human Services - Centers for Disease Control and 
Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) 
infection and HCV related chronic disease. CDC Report1998; 47: 1-39
[13]
Houghton M. Hepatitis C viruses. In: Fields BN, Knipe DM, Howley PM, eds, Fields
Virology (3rd ed). Philadelphia: Lippincott - Raven, 1996: 1035-58.
[14]
Global surveillance and control of hepatitis C. Report of a WHO Consultation 
organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. 
J Viral Hepat 1999; 6: 35-47.
[15]
WHO. HCV genotypes. Available at
http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index2.html#genome; 
accessed July 07, 2014.
[16]
Prati D. Transmission of hepatitis C virus by blood transfusions and other medical 
procedures: a global review. J Hepatol 2006; 45: 607-16.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 52 of 65
[17]
Central and Eastern European Harm Reduction Network (CEEHRN). Hepatitis C 
among drug users in the new EU member states and neighborhood: 
Recommendations for action. CEEHRN brochure/leaflet 2006. Available at 
http://www.aidsactioneurope.org/clearinghouse/topics/hepatitis-c-among-drug-users-
new-eu-member-states-and.
[18]
Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol 1999; 31
(Suppl 1): 17-24.
[19]
Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of 
compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 
2010; 32: 344-55.
[20]
Brown RS. Hepatitis C and liver transplantation. Nature 2005; 436: 973-78.
[21]
Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the 
importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 
29: 908-14.
[22]
Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus 
infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.
[23]
Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the 
burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat 
2014; 21 (Suppl 1): 1-4.
[24]
Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of 
chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
[25]
Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guidelines: diagnosis, 
management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-70.
[26]
Dienstag LJ, McHutchison JG. American gastroenterological association technical 
review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
[27]
Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD practice guidelines: diagnosis, 
management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
[28]
Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces 
risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;
9: 509-16.
[29]
Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological 
response and all-cause mortality among patients with chronic hepatitis C and 
advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
[30]
Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to 
peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or 
compensated cirrhosis. Aliment Pharmacol Ther 2008; 27: 542-51.
[31]
Poynard T, McHutchison JG, Manns M, et al. Impact of pegylated interferon alfa-2b
and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 
2002; 122: 1303-13.
[32]
Shiffman M, Hofmann CM, Thompson EB, et al. Relationship between biochemical, 
virologic and histologic response during interferon treatment of chronic hepatitis C. 
Hepatology 1997; 26: 780-5.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 53 of 65
[33]
Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-
alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective 
study. Hepatology 2007; 45: 579-87.
[34]
Di Bisceglie AM, Shiffman M, Everson GT, et al. Prolonged antiviral therapy with 
peginterferon to prevent complications of advanced liver disease associated with 
hepatitis C: results of the hepatitis C antiviral long-term treatment against cirrhosis 
(HALT-C) trial. Hepatology 2007; 46 (Suppl S1): 290A.
[35]
Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver 
histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 
2004; 39: 333-42.
[36]
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in 
combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis 
Interventional Therapy Group. NEJM 1998; 339: 1485-92.
[37]
Zeuzem S, Feinman SV, Rasenack J, et al. 3HJLQWHUIHURQĮ-2a in patients with chronic 
hepatitis C. NEJM 2000; 343: 1666-72.
[38]
Poynard T, McHutchison JG, Goodman Z, Ling MH, Albrecht J. Is an “à la carte” 
combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment 
in patients with chronic hepatitis C? Hepatology 2000; 31: 211-8.
[39]
Fried MW, Shiffman M, Reddy KR, et al (for the PEGASYS® International Study 
Group). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. 
NEJM 2002; 347: 975-82.
[40]
Manns M, McHutchison JG, Gordon SC et al. PegInterferon alfa-2b plus ribavirin 
compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis 
C: a randomized trial. Lancet 2001; 358: 958-65.
[41]
Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha 2a and ribavirin 
combination therapy in chronic hepatitis C: a randomized study of treatment duration 
and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
[42]
Jacobson IM, McHutchison JG, Dusheiko GM et al. Telaprevir in combination with 
peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of 
phase 3 ADVANCE study. Hepatology 2010; 52 (Suppl S1): 427A.
[43]
Sherman KE, Flamm SL, Afdhal NH et al. Telaprevir in combination with peginterferon 
alfa2b and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients 
who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE
study. Hepatology 2010; 52 (Suppl S1): 401A.
[44]
Poordad F, McCone J, Bacon BR et al. Boceprevir (BOC) combined with peginterferon 
alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C (HCV) genotype 1: 
SPRINT-2 final results. Hepatology 2010; 52 (Suppl S1): 402A.
[45]
EASL Recommendations on Treatment of Hepatitis C 2014. J Hepatol 2014; doi: 
10.1016/j.jhep.2014.05.001 (Epub ahead of print).
[46]
AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C. 2014: 1-
50. Available at http://www.hcvguidelines.org/sites/default/files/full_report.pdf.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 54 of 65
[47]
Jacobson IM, Dore G, Foster G et al. Simeprevir with pegylated interferon alfa 2a plus 
ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection 
(QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 
2014; doi: 10.1016/S0140-6736(14)60494-3 (Epub ahead of print).
[48]
Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 
2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 
infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet 2014; doi: 10.1016/S0140-6736(14)60538-9 (Epub ahead of print).
[49]
Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with Peginterferon and ribavirin leads 
to high rates of SVR in patients with HCV genotype 1 who relapsed after previous 
therapy: a phase 3 trial. Gastroenterology. 2014; 146: 1669-79.
[50]
Reddy KR, Zeuzem S, Zoulim F, et al. A Phase III randomised, double-blind study to 
evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination 
with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 
treatment-experienced patients: the ATTAIN study. Abstract APASL 2014 Brisbane, 
Australia. Available at http://www.natap.org/2014/APASL/APASL_20.htm.
[51]
Full prescribing information Olysio. Available at
http://www.olysio.com/shared/product/olysio/prescribing-information.pdf; accessed 
February 09, 2014.
[52]
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic 
hepatitis C infection. NEJM 2013; 368: 1878-87.
[53]
Lalezari L, Nelson D, Hyland R, et al. Once daily sofosbuvir plus ribavirin for 12 and 24 
weeks in treatment-naive patients with HCV infection: the QUANTUM study. J Hepatol 
2013; 58 (Suppl 1): S346.
[54]
Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C 
genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical 
trial. JAMA 2013; 310: 804-11.
[55]
Menon RM, Klein CE, Lawal AA, et al. Pharmacokinetics and tolerability of the HCV 
protease inhibitor ABT-450 following single ascending doses in healthy adult 
volunteers with and without ritonavir. Abstract of HepDART 2009, Kohala Coast,
Hawaii, USA. Available at http://www.natap.org/2009/hepDART/hepDART_03.htm.
[56]
Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r ombitasvir 
and dasabuvir with ribavirin. NEJM 2014; 370: 1594-603.
[57]
Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-
ombitasvir and dasabuvir with ribavirin. NEJM 2014; 370: 1604-14.
[58]
Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and 
dasabuvir achieves 97% and 100% sustained virologic response with or without 
ribavirin in treatment-experienced patients with HCV genotype 1b infection. 
Gastroenterology 2014; doi: 10.1053/j.gastro.2014.04.045 (Epub ahead of print).
[59]
Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or 
without ribavirin for HCV. NEJM 2014; 370: 1983-92. 
[60]
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin 
for hepatitis C with cirrhosis. NEJM 2014; 370: 1973-82.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 55 of 65
[61]
Hezode C, Marcellin P, Pol S, et al. Results from the phase 2 PEARL-I study:
interferon-free regimens of ABT-450/R + ABT-267 with or without ribavirin in patients 
with HCV genotype 4 infection. J Hepatol 2014; 60 (Suppl 1): S24.
[62]
Hezode C, Fontaine H, Dorival C et al. Effectiveness of telaprevir or boceprevir in 
treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Gastroenterology 2014; 147: 132-42.
[63]
Colombo M, Fernández I, Abdurakhmanov D, et al. Safety and on-treatment efficacy of 
telaprevir: the early access programme for patients with advanced hepatitis C. Gut 
2014; 63: 1150-8.
[64]
Marley J. Efficacy, effectiveness, efficiency. Aust Prescr 2000; 23: 114-5.
[65]
Singal AG, Higgins PDR, Waljee AK. A primer on effectiveness and efficacy trials. Clin
Trans Gastroenterol 2014; 5 (e45): 1-4.
[66]
Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in 
rapid virologic response patients in the large real-world PROPHESYS cohort confirm 
results from randomized clinical trials. Hepatology 2012; 56: 2039-50.
[67]
Thompson AJ, Muir AJ, Sulkowski MS, et al. IL28B polymorphism improves viral 
kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. 
Gastroenterology 2010; 139: 120-9.
[68]
International Committee of Medical Journal Editors. Available at 
http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-
role-of-authors-and-contributors.html; accessed July 07, 2014.

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 56 of 65
Annex 1.
EQ5D-5L
Canada (English) v.2 © 2009 EuroQol Group. EQ-5D™is a trade mark of the EuroQol Group

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 57 of 65
Canada (English) v.2 © 2009 EuroQol Group. EQ-5D™is a trade mark of the 
EuroQol Group

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 58 of 65
Annex 2.
WPAI
Work Productivity and Activity Impairment Questionnaire Hepatitis C, V2.0 
(WPAI: Hepatitis C)

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 59 of 65
WPAI: HepC V2.0 (English for Canada)

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 60 of 65
Annex 3.
PAM-13 Questionnaire Sample 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 61 of 65
Annex 4.
Beliefs Medication Questionnaire (BMQ)
YOUR VIEWS ABOUT  
MEDICINES PRESCRIBED FOR YOUR  
CHRONIC HEPATITIS C 
 
x
We would like to ask you about your personal views about medicines prescribed for your chronic hepatitis C. 
x
These are statements other people have made about their medicines.   
x
Please show how much you agree or disagree with them by ticking the appropriate box. 
 
There are no right or wrong answers.  
We are interested in your personal views  
 
 
 
Views about MEDICINES PRESCRIBED FOR YOUR CHRONIC HEPATITIS C: 
Strongly  
Agree 
Agree 
Uncertain 
Disagree 
Strongly 
Disagree 
N1 
My health, at present, depends on these medicines 
 
 
 
 
 
C1 
Having to take these medicines worries me 
 
 
 
 
 
N2 
My life would be impossible without these medicines 
 
 
 
 
 
C2 
I sometimes worry about the long-term effects of these medicines 
 
 
 
 
 
N3 
Without these medicines I would be very ill 
 
 
 
 
 
C3 
These medicines are a mystery to me 
 
 
 
 
 
N4 
My health in the future will depend on these medicines 
 
 
 
 
 
C4 
These medicines disrupt my life 
 
 
 
 
 
C5 
I sometimes worry about becoming too dependent on these medicines 
 
 
 
 
 
N5 
These medicines protect me from becoming worse 
 
 
 
 
 
 
 
 
YOUR VIEWS ABOUT  
MEDICINES IN GENERAL 
 
x These are statements that other people have made about medicines in general. 
x Please show how much you agree or disagree with them by ticking the appropriate box. 
 
 
 
 
Views about MEDICINES IN GENERAL  
Strongly 
Agree 
Agree 
Uncertain 
Disagree 
Strongly 
Disagree 
GO1 
Doctors use too many medicines 
 
 
 
 
 
GH1 
People who take medicines should stop their treatment for a while every now and 
again 
 
 
 
 
 
GH2 
Most medicines are addictive 
 
 
 
 
 
G02 
Natural remedies are safer than medicines 
 
 
 
 
 
GH3 
Medicines do more harm than good 
 
 
 
 
 
GH4 
All medicines are poisons 
 
 
 
 
 
GO3 
Doctors place too much trust on medicines 
 
 
 
 
 
GO4 
If doctors had more time with patients, they would prescribe fewer medicines 
 
 
 
 
 
 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 62 of 65
Annex 5.
Patient Support Program (PSP) Utilization
Questionnaire
12 weeks treatment: At Interim early post-treatment visit 
24 weeks treatment: At Interim mid treatment visit and Interim early post-treatment visit 
 
Since the last visit, have you utilized any components from the AbbVie Care Patient Support Program? 
 
 No 
Please ignore questions below and return questionnaire to your physician or study nurse 
 
 Yes  
 
Please specify service(s) used: 
 
    Personal support (e.g. Abbvie Care Coach)  
 
    Educational and information material (e.g. magazines, leaflets, diaries) 
 
 Printed 
Please specify how often used:  Usually daily 
 
 Several times per week 
 
 Usually once weekly 
 
 Less than once weekly 

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 63 of 65
Annex 6.
Patient Support Program (PSP) Utilization and -
Satisfaction Questionnaire
12 weeks treatment: At Interim early on-treatment visit, week 12 EoT visit and SVR 12 visit 
24 weeks treatment: At Interim early on-treatment visit, week 24 EoT visit and SVR 12 visit 
 
Since the last visit, have you utilized any components from the AbbVie Care Patient Support Program? 
 
 No 
 
 Please ignore questions below and return questionnaire to your physician or study nurse 
 
 Yes  
 
 What is your level of satisfaction of the AbbVie Care Patient Support Program in general? 
 
 Very good 
 
 Good 
 
 Satisfactory 
 
 Poor 
 
  
 Did the Program address your needs?   Yes, fully    Yes, mostly    No 
 
Please specify service(s) used: 
 
    Personal support (e.g. Abbvie Care Coach)  
 
 Please specify your level of satisfaction: 
 Very good 
 
 Good 
 
 Satisfactory 
 
 Poor 
 
    Educational and information material (e.g. magazines, leaflets, diaries) 
 
 Printed 
Please specify how often used:  Usually daily 
 
 Several times per week 
 
 Usually once weekly 
 
 Less than once weekly 
 
Please specify your level of satisfaction:  Very good 
 
 Good 
 
 Satisfactory 
 
 Poor

Paritaprevir/r – ombitasvir and ± dasabuvir
P15-651 Protocol - Amendment 1
Confidential Information
No use or disclose outside AbbVie is permitted without prior written authorization from AbbVie
Version Canada v 2.0 (12 January 2016)
Page 64 of 65
Annex 7.
Child-Pugh Classification of Severity of Cirrhosis
Parameter
Points Assigned for Observed Findings
1
2
3
Total bilirubin, μmol/L 
(mg/dL)
<34.2 
(<2)
34.2 – 51.3 
(2 – 3)
>51.3
(>3)
Serum albumin, g/L (g/dL)
>35
(>3.5)
28 – 35
(2.8 – 3.5)
<28
(<2.8)
INR
<1.7
1.7 – 2.3
>2.3
Ascites*
None
Slight
Moderate to severe
Hepatic encephalopathy**
None
Grade 1 or 2 
(or suppressed with 
medication)
Grade 3 or 4
(or refractory)
*
None.
Slight ascites = Ascites detectable only by ultrasound examination.
Moderate ascites = Ascites manifested by moderate symmetrical distension of the abdomen.
Severe ascites = Large or gross ascites with marked abdominal distension.
**
Grade 0: normal consciousness, personality, neurological examination, electroencephalogram.
Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cps waves.
Grade 2: lethargic, time-disoriented, inappropriate behavior, asterixis, ataxia, slow triphasic waves.
Grade 3: somnolent, stuporous, place-disoriented, hyperactive reflexes, rigidity, slower waves.
Grade 4: unarousable coma, no personality/behavior, decerebrate, slow 2 to 3 cps delta activity